ReviewAdvances in experimental medicine and biology2026
Salivary Immune and Endocrine Biomarkers in Skin and Mucocutaneous Diseases.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This chapter explores the role of salivary immune and endocrine biomarkers in diagnosing and managing skin and mucocutaneous diseases. These conditions, including allergic, inflammatory, and autoimmune disorders, often present complex diagnostic and therapeutic challenges. Salivary biomarkers offer a promising alternative to traditional blood-based diagnostics, due to their non-invasive sampling method and the ability to reflect both local and systemic immune responses. Key biomarkers, such as cytokines, immunoglobulins, and stress-related hormones, have been identified in saliva and show associations with conditions such as atopic dermatitis, psoriasis, systemic lupus erythematosus, and oral lichen planus. Advancements in salivary diagnostics underscore the potential of biomarkers like IL-17, TNF-α, and cortisol for disease monitoring and personalized treatment approaches. Despite significant progress, challenges remain in standardizing these biomarkers across heterogeneous populations and in implementing cost-effective diagnostic tools into routine clinical practice. Further research is essential to validate the clinical application of these markers, develop reliable point-of-care devices, and design integrated biomarker panels that support early intervention and improve patient outcomes. The growing field of salivary proteomics and exosomal analysis heralds a transformative future for non-invasive, precision-based dermatological diagnostics.
Indexed as
Identifiers
41225101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.